Fierce Pharma Asia—A $410M obesity debut; Another Roche ADC deal; Legend, BeiGene as buyout targets?
A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...
The biotech’s efforts to bring its vaccines to the country mean navigating political pushback in the U.S. and the risk of ...
Here are the five things you need to know, including the national day of mourning for Jimmy Carter, California wildfires, Newbury Street rents, and quality goat time ...
The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...
In the mRNA vaccine maker’s 2024 Shareholder Letter, CEO Stéphane Bancel reflected upon the company’s second year ...
The company is one of a few drugmakers currently developing a vaccine for the illness, which is spreading rapidly through ...
With COVID vaccine sales in the doldrums and a respiratory syncytial virus (RSV) vaccine market in “contraction”, Moderna CEO ...
The challenge of maintaining the earlier growth achieved by US mRNA medicines specialist Moderna through its COVID vaccine ...
(CercleFinance.com) - Moderna a publié sur son site internet une lettre aux actionnaires rédigée par son directeur général, Stéphane Bancel ...
Pour 2025, les priorités de Moderna incluent la maximisation de la disponibilité et de la part de marché de ses vaccins ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback